Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 0402 • ACR Convergence 2022
Opioid Use and Healthcare Utilization in Adults with PsA and AS
Alexis Ogdie¹, Sofia Pedro², Jean Liew³ and Kaleb Michaud⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Boston University, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Opioid use among individuals with spondyloarthritis is common, reported to be ~20-30% in some cohorts. Data on whether this subset of patients have higher…
Abstract Number: 0426 • ACR Convergence 2022
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Jesus Diaz¹, Guillermo Quiceno², Cathy Lee Ching³ and Adela Castro⁴, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³University of Mississippi Medical Center, Jackson, MS, ⁴Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
Abstract Number: 1038 • ACR Convergence 2022
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
Arthur Kavanaugh¹, Xenofon Baraliakos², Sheng Gao³, Warner Chen³, Kristen Sweet³, Soumya Chakravarty⁴, Qingxuan Song³, May Shawi⁵, Frank Behrens⁶ and Proton Rahman⁷, ¹University of California San Diego, San Diego, CA, USA, San Diego, CA, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁷Memorial University, St. John's, NL, Canada
Background/Purpose: Despite overlapping symptoms, axial psoriatic arthritis (axPsA) and ankylosing spondylitis (AS) may be distinct disorders with differing clinical manifestations, genetic associations, and radiographic findings.1…
Abstract Number: 1492 • ACR Convergence 2022
Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
Murat Torgutalp¹, valeria Rios-Rodriguez², Ani Dilbaryan³, Fabian Proft⁴, Mikhail Protopopov⁵, Maryna Verba⁶, Judith Rademacher⁵, Hildrun Haibel¹, Joachim Sieper¹, Martin Rudwaleit⁷ and Denis Poddubnyy⁴, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
Abstract Number: 0014 • ACR Convergence 2022
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
Rick Wilbrink¹, Linda van der Weele², Anneke Spoorenberg¹, Niek De Vries², Frans Kroese¹ and Gwenny Verstappen¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Center Amsterdam, Amsterdam, Netherlands
Background/Purpose: The role of B cells in the pathogenesis of ankylosing spondylitis (AS) remains relatively understudied. Nevertheless, available evidence shows presence of B cells at…
Abstract Number: 0403 • ACR Convergence 2022
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Yu Xue¹, Jiankang Hu², Dongzhou Liu³, Jingyang Li⁴, Huaxiang Wu⁵, Chunyu Tan⁶, Lie Dai⁷, Mengru Liu⁸, Hongying Li⁸ and Hejian Zou¹, ¹Huashan Hospital affiliated to Fudan University, Shanghai, China, ²Jiangxi Pingxiang People’s Hospital, Shanghai, China, ³Shenzhen People’s Hospital （The Second Clinical Medical College of Jinan University）, Shanghai, China, ⁴Zhuzhou Central Hospital, Shanghai, China, ⁵The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, ⁶West China Hospital of Sichuan University, Shanghai, China, ⁷Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, ⁸Eli Lilly and Company, Shanghai, China
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…
Abstract Number: 0428 • ACR Convergence 2022
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Devika dua and Tim Blake, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
Background/Purpose: To determine if there is a significant variation in biologic usage in axSpa patients and to identify factors associated with it.Methods: We collected retrospective…
Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Uta Kiltz¹, Petros P. Sfikakis², Nicola Gullick³, ATHINA THEODORIDOU⁴, Anna Kandyli⁵, Jan Brandt-Juergens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Daniel Peterlik¹⁰, Barbara Schulz¹¹, Effie Pournara¹¹ and Piotr Jagiello¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ³University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁴Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Rheumatology department, University Hospital of Tours, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…
Abstract Number: 0078 • ACR Convergence 2022
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems
Alexis Ogdie¹, Marina Magrey², Robert Fitzsimmons³, Shahrzad Abdollahi⁴, Wai Chung Yong⁵, Yasir Tarabichi⁶, Ana Biljan⁷, Christopher D. Saffore⁷, Kristin Tacelosky⁷ and Jessica Walsh⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, University Hospitals, Richfield, OH, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA, ⁵Division of Rheumatology, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁶Department of Clinical Informatics Research and Education, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁷AbbVie, Inc., North Chicago, IL, ⁸University of Utah, Salt Lake City, UT
Background/Purpose: Most patients with undiagnosed ankylosing spondylitis (AS) seek care for back pain from primary care providers (PCPs), and treatment strategies adopted by PCPs may…
Abstract Number: 0404 • ACR Convergence 2022
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Raphael Micheroli¹, Tim Killeen², Hyejin Jo³, Kenneth Kwok³, Bassel Elzorkany⁴, Caroline Ospelt⁵, Adrian Ciurea⁶ and Michael Nissen⁷, ¹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²Pfizer Ltd, Tadworth, Switzerland, ³Pfizer Inc, New York, NY, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland
Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
Abstract Number: 0429 • ACR Convergence 2022
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Mark Siderius¹, Suzanne Arends², Freke Wink³ and Anneke Spoorenberg², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In patients with ankylosing spondylitis (AS), TNF-α inhibitors influence the course of serum bone turnover markers (BTM), favoring an increase in mineralization during the…
Abstract Number: 1045 • ACR Convergence 2022
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used…
Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Karolina Benesova¹, Oliver Hansen², Uta Kiltz³, Jan Brandt-Juergens⁴, Peter Kästner⁵, Elke Riechers⁶, Daniel Peterlik⁷, Christina Budden⁷, Annika Boas⁷, Stefanie Welle⁷ and Hans-Peter Tony⁸, ¹University Hospital Heidelberg, Heidelberg, Germany, ²Medizinische Abteilung V - Rheumatologie, Universitätsklinikum, Heidelberg, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁶Medizinische Hochschule Hannover, Hannover, Germany, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].